The success of Sildenafil initially sparked a boom for pharma, but recent shifts present a murky picture for shareholders. Off-patent competitors are eroding earnings, and ongoing patent challenges add more complexity https://esmeelcci713487.dgbloggers.com/41608418/the-blue-pill-and-pharma-a-precarious-play